A Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)

Trial Profile

A Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs DCR PH1 (Primary)
  • Indications Primary hyperoxaluria
  • Focus Adverse reactions; First in man
  • Sponsors Dicerna Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2017 Status changed from active, no longer recruiting to discontinued according to a Dicerna Pharmaceuticals media release.
    • 11 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 13 May 2016 According to a Dicerna Pharmaceuticals media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top